Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ad5-ncov
- Development stage
- Phase 4
- Lead developer
- CanSino Biologics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Inhalation
01
Overview
Ad5-nCoV is a recombinant adenovirus type 5 (Ad5) vector-based vaccine developed by CanSino Biologics in collaboration with the Beijing Institute of Biotechnology. The vaccine utilizes a replication-deficient Ad5 vector to deliver the genetic sequence of the SARS-CoV-2 spike (S) protein into host cells. Once expressed, the spike protein induces both neutralizing antibodies and T-cell mediated immune responses to protect against COVID-19. Ad5-nCoV was the first COVID-19 vaccine to enter clinical trials in China and has been developed in both intramuscular (Convidecia) and inhaled aerosol (Convidecia Air) formulations. The inhaled version is designed to induce mucosal immunity in the respiratory tract in addition to systemic immunity.
- Brand names
- ConvideciaConvidecia Air
- Other names
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)PakVac克威莎Keweisha
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ad5-ncov.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ad5-ncov.